Skip to main content

Kalaris Therapeutics, Inc.

KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001754068

No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q3 2026, worth $49.8M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$30.5M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, −2 vs. previous quarter
53
13F valueReported value at the end of Q3 2026
$49.8M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$43.4M
No comparable prior period
Free cash flow, FY2025
-$38.6M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
366.6K
Shares sold short
Change
+60.2K
+19.7% vs. previous
Days to cover
5.43
At average daily volume

Superinvestors holding KLRS, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding KLRS at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Kalaris Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 22, 2026 (view filing)7:47 PM ETMay 202 daysAkkaraju Srinivas and 4 othersDirector, 10% OwnerPPurchase+244.3K$4.83+$1.18M+12.3%2.22M after
Mar 23, 2026 (view filing)Mar 203 daysHagen Brett RChief Accounting OfficerSSale−1.92K$6.72−$12.9K−100.0%0 after
Feb 17, 2026 (view filing)8:15 PM ETDec 18, 202561 daysLateAkkaraju Srinivas and 4 othersDirector, 10% OwnerPPurchase+479.8K$10.42+$5.00M+32.0%1.98M after
Mar 27, 2025 (view filing)Mar 261 dayHagen Brett RChief Accounting OfficerSSale−907$8.97−$8.14K−32.0%1.93K after
Feb 24, 2025 (view filing)Feb 213 daysSinha VikasSee RemarksSSale−303$10.08−$3.05K−0.6%49.1K after
Feb 24, 2025 (view filing)Feb 213 daysHagen Brett RChief Accounting OfficerSSale−96$10.08−$967.68−3.3%2.83K after
Feb 24, 2025 (view filing)Feb 213 daysMiller EdwardGeneral CounselSSale−106$10.08−$1.07K−1.6%6.52K after
Jan 27, 2025 (view filing)Jan 234 daysMiller EdwardGeneral CounselSSale−52$9.50−$493.85−0.8%6.62K after2 lots
Jan 27, 2025 (view filing)Jan 234 daysHagen Brett RChief Accounting OfficerSSale−36$9.50−$342.16−1.2%2.93K after2 lots
Jan 27, 2025 (view filing)Jan 234 daysSinha VikasSee RemarksSSale−129$9.50−$1.23K−0.3%49.4K after2 lots

Top 10 13F holders, Q3 2026

See all 53 holders

The largest institutional positions in Kalaris Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding KLRS in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Samsara BioCapital, LLC12,881,175$37.2M3.54%00.0%Unchanged
RTW Investments, LP1,300,000$3.76M0.04%00.0%Unchanged
Alyeska Investment Group, L.P.472,687$1.37M0.00%−100,000−17.5%Reduced
Siren, L.L.C.356,559$1.03M0.02%−79,239−18.2%Reduced
Vanguard Capital Management LLC330,928$956.4K0.00%−67,784−17.0%Reduced
Ikarian Capital, LLC248,257$717.5K0.14%−111,743−31.0%Reduced
Renaissance Technologies LLC176,863$511.1K0.00%+27,512+18.4%Added
Verdad Advisers, LP140,232$405.3K0.43%+59,935+74.6%Added
UBS Group AG110,187$318.4K0.00%−151,944−58.0%Reduced
Raymond James Financial Inc101,496$293.3K0.00%+4,332+4.5%Added

Holders of 5% or more of KLRS

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Kalaris Therapeutics, Inc..

Largest holders of KLRS from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Samsara BioCapital, L.P.13D/A54.20%12.9M shares−2.30 ppfrom 56.50%Mar 25, 20254 filingsMay 22, 2026SEC
RTW Investments, LP13G5.70%1.30M sharesNewFeb 17, 20261 filingFeb 17, 2026SEC
Coastlands Capital LP13G5.69%1.36M sharesNewOct 26, 20261 filingOct 26, 2026SEC